Cancer Biology & Medicine

►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".


►►Very important notification on publication fee

Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.

Cancer Biology & Medicine

Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

Author Benefits

● Easy submission via online system

● Efficient and professional peer review

● Rapid pre-print online publication

● No charge for publication and open access

● International visibility-All full texts are free in PubMed Central




Publication of the 3rd issue in 2020


As a global public health event, coronavirus disease (COVID-19) pandemic affects people’s health and routine life severely this year. For cancer patients with COVID-19, it’s very important to study their risks, clinical features, therapeutics, medical cares, and so on. In this issue, Prof. Xiaoping Miao and Xiaojiang Cui contribute an editorial and a review on this topic, respectively.

Several papers on basic researches focus the roles of some molecules in the tumorigenesis and cancer development, such as CMTM family proteins, Anoctamin 7 (ANO7), PRAS40, and SHP2. What’s more, reviews and original researches on clinical oncology would be attractive as well to readers. The contents refer to management strategy for papillary thyroid microcarcinoma, immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients, and outcomes of patients treated with SVILE vs. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type.

We hope this issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine.

Posted: 2020-08-14

New impact factor: 5.432


According to the Journal Citation Reports (2020), the Impact Factor (2019) of Cancer Biology & Medicine is 5.432, locating in Q1 areas of both Medicine, Research & Experimental category (ranking 20/138) and Oncology category (ranking 52/244).

As a peer-reviewed open-access journal, Cancer Biology & Medicine is quarterly published by China Anti-Cancer Association and Tianjin Medical University Cancer Institute and Hospital. It focuses on translational cancer research, dedicating to narrowing the gap between bench and bedside. Except for SCIE, the journal has been indexed in PubMed/ PubMed Central, BIOSIS Previews, SCOPUS, DOAJ, and Chemical Abstracts. Meanwhile, it is also a member of the Committee on Publication Ethics (COPE) and CrossRef.

Welcome to submit your work to Cancer Biology & Medicine and communicate with your colleagues worldwide via our platform. 


Posted: 2020-06-30
More Announcements...

Vol 17 (2020): Online first articles

Table of Contents


Radiotherapy in combination with systemic therapies for brain metastases: current status and progress PDF
Lei Liu, et al. 1-13
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges PDF
Yi Ba, et al. 1-14
Evolving insights: How DNA repair pathways impact cancer evolution PDF
Jiadong Zhou, et al. 1-22
Emerging data supporting stromal cell therapeutic potential in cancer: reprogramming stromal cells of the tumor microenvironment for anti-cancer effects PDF
Armel H. Nwabo Kamdje, et al. 1-14
Adaptive response of resistant cancer cells to chemotherapy PDF
Yi-Jye Chern, et al. 1-22

Original Article

Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines PDF
Natalia Vargas-Rondón, et al. 1-22
Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer PDF
Jing Zhao, et al. 1-13
The IL-33/ST2 axis affects tumor growth by regulating mitophagy in macrophages and reprogramming their polarization PDF
Huadan Xu, et al. 1-13
The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer PDF
Yue Fan, et al. 1-19
A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer PDF
Qiang Ruan, et al. 1-10
The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency PDF
Yayun Gu, et al. 1-14
The m6A methylation landscape stratifies hepatocellular carcinoma into 3 subtypes with distinct metabolic characteristics PDF
Xiaotian Shen, et al. 1-16
Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma PDF
Ting Han, et al. 1-17